Vitiligo Treatment: Lynk Pharma Begins Phase II Clinical Trial of LNK01004 Ointment
Beyond vitiligo, Lynk Pharmaceuticals is also advancing the clinical development of LNK01004 for other inflammatory skin conditions, including chronic hand eczema.
E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Beyond vitiligo, Lynk Pharmaceuticals is also advancing the clinical development of LNK01004 for other inflammatory skin conditions, including chronic hand eczema.
AbbVie has received a positive CHMP opinion for upadacitinib (RINVOQ) to treat adults and adolescents with severe alopecia areata and non-segmental vitiligo, with a final European Commission decision expected in the coming months.
HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.

